11:30 am – 12:30 pm Friday, October 29

Joint Topic: Anticoagulation Therapy Anticoagulation Alphabet Soup: VKAs, LMWHs, and DOACs (214-1)

Treatment of thrombosis in pediatric patients presents many challenges. Thrombosis in pediatric patients has a wide range of etiologies, and researchers lack consensus about duration of therapy based on the thrombosis location and the presence of risk factors. Most patients under 18 years of age are treated with either parenteral low-molecular-weight heparins (LMWH) or vitamin K antagonists (VKAs).

Read more...
Speaker:
Ashleigh Brown, BSN RN CPN CPHON®
CNE Hours
1
RX Hours
0.25
2:15 – 3:15 pm Saturday, October 30

Treating Smarter, Not Harder: Abandoning Intensification and Replacing with Immunotherapy for Patients with Down Syndrome and B-ALL (C234)

coglogoChildren with Down syndrome (DS) have a striking predisposition for developing acute leukemia, with a 40-fold increased risk of developing acute lymphoblastic leukemia (ALL) compared to non-DS patients (Wadhwa et al, 2017). Approximately 3% of children with ALL have DS, and these children have inferior outcomes and higher rates of treatment-related mortality (TRM) and are at greater risk of relapse (Buitenkamp et al., 2014).

Read more...
5:00 – 6:00 pm Thursday, October 28

Lighting the Way in COG with MATCH: Targeted Therapies in Pediatric CNS Tumors (C211)

coglogoPediatric MATCH (Molecular Analysis for Therapy Choice) is a joint effort between the National Cancer Institute (NCI) and Children’s Oncology Group (COG) matching targeted therapies to specific tumor genomic sequencing in patients with relapsed or refractory solid tumors, non-Hodgkin lymphomas, brain tumors, and histiocytic disorders.

Read more...
3:30 – 4:30 pm Friday, October 29

Paper Presentation: Long Term (or Chronic) Supportive Care — Long-term Anticoagulation in Children Utilizing Fondaparinux-A Single Pediatric Center Experience (222-3)

Fondaparinux is a synthetic, subcutaneously administered heparinoid that selectively inhibits activated factor X. Pediatric studies of fondaparinux have shown safety and efficacy profiles for the treatment of venous thromboembolism that was similar to standard pediatric anticoagulants.

Read more...
3:30 – 4:30 pm Friday, October 29

Paper Presentation: Long Term (or Chronic) Supportive Care — Individualized Pain Plans in Managing Pain in Patients with Sickle Cell Disease (222-2)

Vaso-occlusive crisis (VOC) is the leading cause of hospital admissions in pediatric patients with sickle cell disease (SCD). Achieving the maximum opioid dose earlier in the admission is associated with shorter lengths of stays, allowing children suffering from SCD to spend less time in the hospital and decreasing their risk for depression and other long-term hospital-associated complications.

Read more...
5:00 – 6:00 pm Thursday, October 28

Paper Presentation: Child/Adolescent Cancer Treatment Experience — Do CSF Biomarkers Relate to Measures of Cognitive Function in Children During Maintenance Therapy for Leukemia? (210-3)

Children treated for acute lymphocytic leukemia (ALL) receive central nervous system–directed chemotherapy, which is a known risk factor for cognitive dysfunction. ALL chemotherapy treatment is also associated with changes in biomarkers of inflammation and oxidative stress, which may underlie changes in neurocognitive functioning.

Read more...
5:00 – 6:00 pm Thursday, October 28

Paper Presentation: Child/Adolescent Cancer Treatment Experience — Analysis of AYA Cancer Patient Priority Symptoms Using Text Mining Software (210-2)

The symptoms associated with cancer treatment are a major concern for the adolescent and young adult (AYA) population. Understanding these distinct symptom experiences, especially AYAs' priority symptoms—those that take the forefront of a patient’s concern—can support healthcare providers in providing personalized care.

Read more...
Speaker:
Kylie Bethards
CNE Hours
1
5:00 – 6: 00 pm Thursday, October 28

Paper Presentation: Child/Adolescent Cancer Treatment Experience — Qualitative Content Analysis of Daily Journaling by Children with Cancer Using a Game-Based App (210-1)

The consequences of cancer persist beyond the clinical setting. Resources to assess the child’s quality of life and markers of well-being outside of the clinical setting can support a more personalized approach to care. Color Me Healthy is a new, game-based symptom assessment app that was co-designed by children with cancer and pediatric oncology clinicians.

Read more...
Speaker:
Kaitlyn Fox, BSN RN
CNE Hours
1
Subscribe to this RSS feed